JNJ-26483327 / J&J - LARVOL DELTA

A risk score prognostic model based on four ubiquitination and immune-related genes in sepsis for outcome prediction and treatment guidance. (PubMed, Int Arch Allergy Immunol) - "The 4 ubiquitination and immune-related model genes may play an important role in sepsis by regulating immune cell infiltration and immune and inflammatory related pathways. The model constructed based on these 4 genes has good predictive value, which may help clinical doctors better evaluate the prognosis of sepsis patients and develop personalized treatment plans."

Journal • Infectious Disease • Inflammation • Septic Shock • Targeted Protein Degradation

MULTI-BIOINFORMATICS REVEALED DRUGGABLE PROTEIN NETWORK OF PROGRESSION FROM GASTRIC INTESTINAL METAPLASIA TO GASTRIC ADENOCARCINOMA (UEGW 2024) - "Computational drug repurposing of approved and investigational drugs/compounds (e.g., as found on www.clinicaltrials.gov) identified the following drugs as effective for GIM: dasatinib with or without erlotinib, nilotinib, afatinib on SRC, SM1-71 on SRC, JNJ-26483327 on EGFR, Afatinib on EGFR, ingenol mebutate on protein kinase C (PKC) family, amoxapine, benoxaprofen, avobenzone, amlexanox, alprazolam, praziquantel, ibuprofen piconol, tranilast, and restoril. The druggable protein network associated with GIM progression toward GA was identified. The distinct phenotypic patterns between GIM and GA might challenge the notion that GIM serves as the primary precancerous lesion in GA tumorigenesis rather than shares a common cause with tissue-resident stem cells. Further validation of the druggable protein network is needed for the development of a cost-effective surveillance program and preventive treatment of the GIM-to-GA progression."

IO biomarker • Breast Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRCA1 • CD44 • CTNNB1 • EGFR • JUN • RBP2 • SRC

GASTRIC INTESTINAL METAPLASIA VS GASTRIC ADENOCARCINOMA IN PATIENTS: DISTINCT PHENOTYPIC TRAITS IN TRANSCRIPTOMICS (DDW 2023) - "The results of the present study did not support the dogma that GIM is the essential precancerous lesion in GA tumorigenesis and suggested possible drug repurposing for treatment of GIM."

Clinical • IO biomarker • Gastric Adenocarcinoma • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRCA1 • CD8 • EGFR • HLA-DPA1 • HLA-DPB1 • HLA-DQB1 • HNF1A • PPARGC1A • RBP2

Drug repurposing for rheumatoid arthritis: Identification of new drug candidates via bioinformatics and text mining analysis. (PubMed, Autoimmunity) - "We hypothesize that the FDA-approved drugs momelotinib, ibrutinib, and sodium butyrate may be promising candidates for RA. In addition, CHEMBL306380, Compound 19a (CHEMBL3116050), ME-344, XL-019, TG100801, JNJ-26483327, and NV-128 were identified as novel repurposing candidates for the treatment of RA. Preclinical and further validation of these drugs may provide new treatment options for RA."

Journal • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology